UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

The New England journal of medicine, 2022-12, Vol.387 (24), p.2220-2231

2022

Volltextzugriff (PDF)

IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions

Nature immunology, 2017-08, Vol.18 (8), p.889-898

2017

Volltextzugriff (PDF)

A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity

eLife, 2019-11, Vol.8

2019

Volltextzugriff (PDF)

Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies

Clinical cancer research, 2019-02, Vol.25 (4), p.1174-1184

2019

Volltextzugriff (PDF)

How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy

Blood, 2020-03, Vol.135 (11), p.804-813

2020

Volltextzugriff (PDF)

B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy

Clinical cancer research, 2017-08, Vol.23 (15), p.4212-4223

2017

Volltextzugriff (PDF)

A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma

Annals of oncology, 2015-08, Vol.26 (8), p.1667-1677

2015

Volltextzugriff (PDF)

BH3 Profiling Identifies Three Distinct Classes of Apoptotic Blocks to Predict Response to ABT-737 and Conventional Chemotherapeutic Agents

Cancer cell, 2007-08, Vol.12 (2), p.171-185

2007

Volltextzugriff (PDF)

Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species

Cancer research (Chicago, Ill.), 2007-06, Vol.67 (11), p.5408-5417

2007

Volltextzugriff (PDF)

Hypofractionated radiotherapy for refractory or relapsed aggressive B-cell lymphoma in the rituximab era

BMC cancer, 2024-01, Vol.24 (1), p.72-72, Article 72

2024

Volltextzugriff (PDF)

A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma

Clinical cancer research, 2008-10, Vol.14 (20), p.6697-6703

2008

Volltextzugriff (PDF)

Rituximab extended schedule or retreatment trial for low tumour burden non‐follicular indolent B‐cell non‐Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402

British journal of haematology, 2016-06, Vol.173 (6), p.867-875

2016

Volltextzugriff (PDF)

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

Nature medicine, 2002-01, Vol.8 (1), p.68-74

2002

Volltextzugriff (PDF)

Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival

Blood, 2006-12, Vol.108 (13), p.4178-4186

2006

Volltextzugriff (PDF)

Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype

Haematologica (Roma), 2010-08, Vol.95 (8), p.1342-1349

2010

Volltextzugriff (PDF)

Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma

Cancer discovery, 2024-09, Vol.14 (9), p.1577-1580

2024

Volltextzugriff (PDF)

Determinants of outcomes and advances in CD19‐directed chimeric antigen receptor therapy for B‐cell acute lymphoblastic leukemia

European journal of haematology, 2024-01, Vol.112 (1), p.51-63

2024

Volltextzugriff (PDF)

FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma

Blood, 2006-10, Vol.108 (8), p.2720-2725

2006

Volltextzugriff (PDF)

Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma

Journal of clinical oncology, 2006-07, Vol.24 (19), p.3121-3127

2006

Volltextzugriff (PDF)

Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients

Blood, 2007-04, Vol.109 (7), p.2773-2780

2007

Volltextzugriff (PDF)

Role of Bruton's tyrosine kinase in B cells and malignancies

Molecular cancer, 2018-02, Vol.17 (1), p.57-57, Article 57

2018

Volltextzugriff (PDF)

Lenalidomide for the treatment of B-cell lymphoma

Expert opinion on investigational drugs, 2016-09, Vol.25 (9), p.1103-1116

2016

Volltextzugriff (PDF)

1 – 25 von 13.340

Suche als RSS-Feed

Aktive Filter

ThemaPrognosis

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(11.691)
Mit Volltextzugriff
(10.145)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(12.442)
Science & Technology
(10.677)
Life Sciences & Biomedicine
(10.450)
Male
(6.061)
Female
(5.689)
Oncology
(4.853)
Middle Aged
(4.596)
Lymphoma, Large B-Cell, Diffuse - Drug Therapy
(4.518)
Aged
(3.943)
Hematology
(3.836)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(3.561)
Adult
(3.429)
Lymphoma
(3.100)
Biological And Medical Sciences
(2.932)
Medical Sciences
(2.915)
Lymphoma, B-Cell - Drug Therapy
(2.834)
Rituximab
(2.360)
Treatment Outcome
(2.347)
Antineoplastic Agents - Therapeutic Use
(1.909)
Hematologic And Hematopoietic Diseases
(1.879)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(12.882)
EZB Electronic Journals Library
(6.792)
Journals@Ovid Complete
(5.383)
IngentaConnect
(4.626)
NUS Single-Journal Subscriptions
(2.978)
IngentaConnect Journals
(2.233)
Wiley Online Library - AutoHoldings Journals
(1.840)
Wiley Online Library Full Collection 2018
(1.543)
Elsevier ScienceDirect Journals Complete
(1.495)
SpringerLink_现刊
(1.478)
Taylor & Francis Journals
(1.027)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(1.025)
Taylor & Francis
(962)
Taylor & Francis:Master (3349 titles)
(853)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(830)
Nature Journals
(614)
Nexis Uni
(605)
Oxford journals
(254)
BMJ Journals
(237)
SpringerLink Series
(219)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(18)
... seit 90 Tagen
(76)

Menü

Weitere Dienste

Einstellungen

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity

Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies

How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy

B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy

A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma

BH3 Profiling Identifies Three Distinct Classes of Apoptotic Blocks to Predict Response to ABT-737 and Conventional Chemotherapeutic Agents

Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species

Hypofractionated radiotherapy for refractory or relapsed aggressive B-cell lymphoma in the rituximab era

A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma

Rituximab extended schedule or retreatment trial for low tumour burden non‐follicular indolent B‐cell non‐Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival

Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype

Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma

Determinants of outcomes and advances in CD19‐directed chimeric antigen receptor therapy for B‐cell acute lymphoblastic leukemia

FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma

Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma

Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients

Role of Bruton's tyrosine kinase in B cells and malignancies

Lenalidomide for the treatment of B-cell lymphoma

Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B‐cell non‐Hodgkin lymphomas, ANRS HC‐13 lympho‐C study

Aktive Filter

Suchergebnisse filtern